Century Therapeutics, Inc.

IPSC

NASDAQ

Healthcare

Biotechnology

Philadelphia, PA, US140 employeescenturytx.com

$2.15

-0.04(-2.05%)

Mkt Cap $186M

$0.39

$2.94

52-Week Range

At a Glance

AI-generated

Century Therapeutics, Inc.

Revenue breakdown: Single Reportable Segment (100%).

8-K

Century Therapeutics, Inc. filed an 8-K on March 12, 2026, furnishing Item 2.02 with Exhibit 99.1 press release and Item 7.01 with Exhibit 99.2 investor presentation, both not deemed 'filed' under Section 18 of the Securities Exchange Act. The filing discloses results of operations and other investor information via exhibits.

$186M

Market Cap

$109M

Revenue

-$10M

Net Income

Employees140

Fundamentals

How The Business Makes Money

Revenue by Segment

Single Reportable Segment100%($116M)

Activity

What Changed Recently

Financial Results

Mar 11, 2026

(including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “

Shareholder Vote

Jan 22, 2026

Submission of Matters to a Vote of Security Holders. On January 22, 2026, Century Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the

Regulation FD

Jan 11, 2026

Regulation FD Disclosure. On January 12, 2026, Century Therapeutics, Inc. (the “Company”) updated information reflected in a slide presentation, which is attach

Material Agreement+3 More

Jan 7, 2026

Entry into a Material Definitive Agreement. On January 7, 2026, Century Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “P

Peer Companies

Company	Price	Change	Market Cap	P/E
EQEquillium, Inc.	$1.97	-3.43%	$70M	-3.0
KPTIKaryopharm Therapeutics I...	$5.88	+1.03%	$50M	-0.6
OSTXOS Therapies Incorporated	$1.37	+0.74%	$48M	—
TELOTelomir Pharmaceuticals, ...	$1.27	-3.79%	$44M	-4.2
COEPCoeptis Therapeutics Hold...	$11.94	+5.85%	$42M	-3.9
SNTISenti Biosciences, Inc.	$0.87	+3.56%	$23M	-0.5
CUECue Biopharma, Inc.	$0.18	-11.20%	$14M	-1.1
GNTAGenenta Science S.p.A.	$0.69	-0.73%	$13M	-1.2

Analyst View

Company Profile

CIK0001850119

ISINUS15673T1007

CUSIP15673T100

Phone267 817 5790

Address3675 Market Street, Philadelphia, PA, 19104, US

SEC EDGAR